ReviewJournal of personalized medicine2022
Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A Systematic Review and Meta-Analysis of Oncologic Liver Resections in Low- and Middle-Income Countries: Opportunities to Improve Evidence and Outcomes.Journal of surgical oncology · 2025Pooled it
- Pooled it
- Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.Journal of translational medicine · 2025Trial
- Review
- Successful treatment of β-catenin-positive, immune checkpoint inhibitor-resistant tumor in a case of multicentric hepatocellular carcinoma.Clinical journal of gastroenterology · 2026Article
- Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Artificial intelligence-driven CT radiomics model predicts prognosis in TACE-refractory hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.ESMO gastrointestinal oncology · 2026Article
- A review of established and new developments in local therapies for liver cancer.ESMO gastrointestinal oncology · 2026Review
- Construction and external validation of a prognostic model for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization: a multicenter retrospective cohort study.World journal of surgical oncology · 2026Article
- Outcomes of Preoperative TACE vs Upfront Hepatectomy in Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam.Journal of hepatocellular carcinoma · 2026Article
- Noninvasive Prediction of High Ki-67 Expression in Hepatocellular Carcinoma Using Multiparametric MRI and Clinical Biomarkers.Journal of hepatocellular carcinoma · 2026Article
- Article
- Should We Fear the Frail? A Review on the Impact of Frailty on Liver Surgery.Medical sciences (Basel, Switzerland) · 2025Review
- Selective Angiographic Roadmap Analysis (SARA) of Hepatocellular Carcinoma Feeding Arteries for Transarterial Chemoembolization.Diagnostics (Basel, Switzerland) · 2025Review
- Advancing predictive oncology: Integrating clinical and radiomic models to optimize transarterial chemoembolization outcomes in hepatocellular carcinoma.World journal of clinical cases · 2025Article
- Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions.Journal of clinical medicine · 2025Review
- Review
- Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization.Journal of clinical laboratory analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient's health status. Surgical resection, transplantation, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.